CLLS vs. AMRN, AQST, PRTA, TERN, PRME, HUMA, SNDL, HRTX, AURA, and ALT
Should you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Amarin (AMRN), Aquestive Therapeutics (AQST), Prothena (PRTA), Terns Pharmaceuticals (TERN), Prime Medicine (PRME), Humacyte (HUMA), SNDL (SNDL), Heron Therapeutics (HRTX), Aura Biosciences (AURA), and Altimmune (ALT). These companies are all part of the "pharmaceutical products" industry.
Cellectis vs. Its Competitors
Amarin (NASDAQ:AMRN) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.
Amarin has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 2.91, suggesting that its stock price is 191% more volatile than the S&P 500.
Amarin currently has a consensus price target of $12.00, suggesting a potential downside of 28.70%. Cellectis has a consensus price target of $4.00, suggesting a potential upside of 148.45%. Given Cellectis' stronger consensus rating and higher possible upside, analysts clearly believe Cellectis is more favorable than Amarin.
22.3% of Amarin shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 2.0% of Amarin shares are held by insiders. Comparatively, 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Cellectis had 1 more articles in the media than Amarin. MarketBeat recorded 2 mentions for Cellectis and 1 mentions for Amarin. Cellectis' average media sentiment score of 0.37 beat Amarin's score of -0.13 indicating that Cellectis is being referred to more favorably in the news media.
Cellectis has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.
Amarin has a net margin of -41.07% compared to Cellectis' net margin of -114.82%. Amarin's return on equity of -17.21% beat Cellectis' return on equity.
Summary
Cellectis beats Amarin on 12 of the 16 factors compared between the two stocks.
Get Cellectis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectis Competitors List
Related Companies and Tools
This page (NASDAQ:CLLS) was last updated on 7/8/2025 by MarketBeat.com Staff
Free CLLS Stock Alerts